A newly developed low dose T1W-DCE-MRI method, ACcomb, was used to estimate the absolute CBF of vestibular schwannomas (VS) and normal appearing brain tissue in a group of 12 consecutive type 2 neurofibromatosis (NF2) patients, undergoing anti-angiogenic bevacizumab treatment. This new method consistently displayed excellent gray-white matter flow contrast and produced mean GM and WM CBF estimates consistent with previous literature values. Use of this new method showed that at 90 days post bevacizumab treatment, there was increased positive correlation between CBF and estimated plasma volume within the VS, and a significant increase in CBF within normal appearing white matter.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords